Press Releases April 7, 2026 08:00 PM

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical Announces Participation in Key Investor Conferences in April 2026

By Avery Klein COLL
Collegium to Participate in Upcoming Investor Conferences
COLL

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its management will participate in the 25th Annual Needham Virtual Healthcare Conference and Piper Sandler Spring Biopharma Symposium. The company highlighted its growth strategy centered on its neuropsychiatry business, especially Jornay PM, and plans to grow its commercial portfolio responsibly.

Key Points

  • Collegium will participate in two major investor conferences in April 2026, providing exposure to investors and analysts.
  • The company is focusing on expanding its neuropsychiatry business with Jornay PM, a differentiated ADHD treatment, as the lead growth driver.
  • Collegium emphasizes disciplined capital deployment and diversification of its biopharmaceutical portfolio, including responsible pain management medications.

STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

25th Annual Needham Virtual Healthcare Conference
Fireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m. ET
Virtual

A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

Piper Sandler Spring Biopharma Symposium
Thursday, April 16, 2026
Boston, MA

About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:
Ian Karp
Head of Investor Relations
[email protected]

Danielle Jesse
Director, Investor Relations
[email protected]

Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
[email protected]


Risks

  • Market reception to investor presentations and the company's growth strategy is uncertain and may impact stock performance.
  • Competition in neuropsychiatry and pain management sectors may affect commercial success of products like Jornay PM.
  • Regulatory and execution risks related to expanding the commercial portfolio and capital deployment could impact future financial results.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026